Alpine Saxon Woods Dividend Strategy

Overview

The Dividend strategy invests in companies that have maintained or increased dividends for at least the past 5 years. Fundamental research is performed on each company’s ability to sustain its dividend and potentially increase those payments in the future, incorporating analysis on free cash flow and numerous balance sheet metrics. The strategy is market capitalization and sector agnostic, but the nature of dividend paying companies tends to tilt towards a mid-to-large capitalization profile.  

‍

Investment Objectives

The objective of the Strategy is to generate high current income, growth of income, and capital preservation by investing in high-quality companies that pay attractive dividends and have the potential to increase those dividends over time. This approach aims to provide consistent returns, especially during market volatility.

‍

Portfolio Construction

The portfolio is constructed using liquid, publicly traded stocks and is typically fully invested. Positions are generally initiated at weights of 3% to 5%, with the portfolio normally holding between 35 and 45 securities. To maintain diversification and manage risk, individual security positions are generally limited to no more than 10% of portfolio assets, while sector exposure is limited to 25% of the portfolio or 1.5 times the benchmark weighting, whichever is greater. Quantitative risk management statistics are regularly reviewed to identify where portfolio risks exist and to evaluate the sources and magnitude of those risks.

‍

Risk management is an ongoing component of the investment process. Portfolio holdings are continuously monitored, and investment theses are formally reviewed when a stock declines 15% from its initial purchase price. This review is intended to determine whether the original investment rationale remains intact and whether the risk-reward profile continues to be attractive.

‍

Securities may be sold for several reasons, including changes in company fundamentals, deterioration in operating or financial health, or when the original investment thesis is no longer valid. Positions may also be exited when anticipated catalysts fail to materialize or are no longer expected to drive future value creation. In addition, holdings may be reduced or eliminated when they reach the team's valuation target. Portfolio diversification guidelines, including individual security and sector exposure limits, are also considered as part of the sell discipline and ongoing portfolio management process.

Documents

As of

September 30, 2026

Dividend Strategy Factsheet
Dividend Strategy Commentary
Strategy Spotlight: Dividends
Dividend Strategy GIPS Composite Report
No items found.

Quick Facts

As of

September 30, 2026

Fund
SMA Inception Date
1/1/2019
Benchmark 1
S&P Dividend ETF (SDY)
Benchmark 2
iShares Russell 1000 Value ETF (IWD)
Strategy AUM
$86.10M
Investment Minimum
Negotiable
Fees
Negotiable

Meet the Team

Mark T. Spellman
  • 32 years industry experience
  • BS: Boston College
  • MBA: UMass Amherst
View More
Brian Hennessey, CFA
  • 27 years industry experience
  • BA: Williams College
  • MBA: M.I.T.
View More
Sarah Hunt, CFA, CFP®
  • 26 years industry experience
  • BA: Wesleyan University
  • MBA: Fordham University
View More
Ronak Jain, CFA
  • 17 years industry experience
  • BBA: Macaulay Honor College at Baruch College

‍

View More

Characteristics

As of

September 30, 2026

Strategy
Benchmark 1
Number of Holdings
38
155
Median Market Cap ($B)
88.25
20.48
TTM Dividend Yield
2.86
%
2.98
%
1-Year Dividend Growth
6.05
5.41
5-Year Dividend Growth
6.63
6.3
P/E 1-Year Forward
18.19
17.29
Free Cash Flow Yield
4.29
%
4.36
%
Total Debt/EBITDA
3.43
2.97
Annual Turnover
72.15
–

Sector Analysis

As of

September 30, 2026

Strategy
Benchmark 1
Healthcare
17.4
%
8.4
%
Financials
16.0
%
12.2
%
Technology
14.9
%
8.7
%
Industrials
13.5
%
18.5
%
Consumer Staples
10.1
%
15.9
%
Materials
9.0
%
7.4
%
Real Estate
6.4
%
4.0
%
Utilities
5.4
%
12.9
%
Consumer Discretionary
4.2
%
5.1
%
Energy
3.1
%
3.7
%
Communications
0.0
%
3.2
%

Top 10 Holdings

As of

September 30, 2026

Fund
JPMORGAN CHASE & CO
4.2
%
AMGEN INC
4.1
%
ABBVIE INC
3.8
%
MEDTRONIC PLC
3.8
%
EMERSON ELECTRIC CO
3.7
%
CISCO SYSTEMS INC
3.3
%
WILLIAMS COS INC
3.1
%
ABBOTT LABORATORIES
3.1
%
MONDELEZ INTERNATIONAL INC-A
3.1
%
MICROSOFT CORP
2.9
%
TOTAL
35.1
%

Risk/Returns Metrics

As of

September 30, 2026

Strategy
Benchmark 1
Alpha
3.28
%
–
Beta
0.91
1.00
Sharpe Ratio
0.50
0.31
Standard Deviation
14.25
%
14.61
%
Up/Down Capture
98/85
–

Average Annual Total Return

As of

September 30, 2026

As of

October 31, 2026

YTD
1 Year
3 Year
5 Year
Since Inception
Gross
8.80
%
10.80
%
18.03
%
11.10
%
10.90
%
Net (Composite)
8.14
%
9.86
%
16.96
%
10.08
%
9.89
%
Benchmark 1
7.24
%
7.33
%
11.26
%
7.28
%
9.49
%
Benchmark 2
19.12
%
23.67
%
19.86
%
11.73
%
13.21
%
YTD
1 Year
3 Year
5 Year
Since Inception
Gross
16.38
%
18.26
%
22.03
%
11.37
%
11.73
%
Net (Composite)
15.39
%
17.25
%
20.92
%
10.32
%
10.69
%
Benchmark 1
17.66
%
20.19
%
15.79
%
8.28
%
10.69
%
Benchmark 2
24.27
%
28.40
%
23.03
%
11.56
%
13.67
%

The Quarter's Top Contributors

As of

September 30, 2026

Software behemoth Microsoft (MSFT) was a top contributor in the quarter. The company reported better-than expected sales and earnings, putting investors’ minds at ease over its massive AI capital spending program. Its Azure cloud business showed revenue accelerating while its AI assistant Copilot showed better-than-expected commercial rollout results. These results illustrated the potential ROI for its capital spending plan. We continue to like the MSFT story as it begins to show tangible financial results of how it is benefiting from its AI spending. Biotech drug firm Amgen (AMGN) was also a top contributor during the quarter. AMGN reported better than expected revenue and earnings and is on pace to generate more than $10B in free cash flow for 2026. Test results for its once-a-month obesity drug, MariTide, were positive and could give it a unique entry into the obesity market. Early Phase III results for its autoimmune disease drug were also positive and could conceivably give it a new path for entry into the treatment of numerous autoimmune diseases. We continue to like AMGN given its recent execution and robust R&D pipeline. Shares of Garmin (GRMN) were also a major contributor in the quarter. Record sales in its fitness division that handily beat expectations, coupled with significantly higher gross and operating margins, drove the shares higher as the company raised expectations for 2027. Its acquisitions in the premium endurance and training segments are further solidifying its strength in personal fitness.

‍

The Quarter's Top Detractors

As of

September 30, 2026

Diesel engine and power unit producer Cummins (CMI) also underperformed in the quarter due to weakness in the aforementioned AI-related trade. As with LRCX, its results and order book remain strong but sentiment turned against the theme in 3Q. We continue to like the prospects for CMI and continue to hold the shares. Shares of Brookfield Renewable (BEPC), which were purchased earlier in 3Q, detracted from the strategy’s performance for the quarter. While we feel the healthy 5.56% dividend yield is attractive, interest rate spikes late in the quarter hurt most utilities and dividend-paying stocks. We still see good value in BEPC and continue to hold shares, despite our mistiming of its initial purchase. Defense contractor L3Harris (LHX) underperformed for the second consecutive quarter after starting off the year strongly when it benefited from war in the Middle East. The prospects for the end of hostilities and slower defense budget growth caused weakness in the shares. Its CEO was also fired during the quarter after an investigation into his personal conduct. We sold our entire position in LHX during the quarter as the company looks to get back on track in several capacities.